HLS Therapeutics (TSE:HLS) Shares Up 2.2% – Still a Buy?

HLS Therapeutics Inc. (TSE:HLS) shares traded up 2.2% during trading on Tuesday . The stock traded as high as C$4.23 and last traded at C$4.20. 9,200 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 20,629 shares. The stock had previously closed at C$4.11.

HLS Therapeutics Price Performance

The company has a debt-to-equity ratio of 75.00, a current ratio of 1.00 and a quick ratio of 1.01. The stock’s fifty day simple moving average is C$4.38 and its 200-day simple moving average is C$4.48. The company has a market capitalization of C$131.35 million, a P/E ratio of -13.12 and a beta of -0.15.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings results on Friday, May 15th. The company reported C($0.10) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. The business had revenue of C$17.88 million during the quarter. On average, equities analysts forecast that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.